Monteverde & Associates Launches Investigation into BioLife Sale
Shareholders of BioLife Solutions, Inc. face a proposed acquisition by Repligen Corporation, prompting scrutiny from New York-based Monteverde & Associates PC. The firm is evaluating the fairness of the deal, which offers investors $11.25 in cash and 0.1442 shares of Repligen stock per BioLife share held.
The investigation centers on whether the acquisition terms adequately protect the interests of current BioLife stockholders. Juan Monteverde, whose firm was ranked among the top 50 in the 2025 ISS Securities Class Action Services Report, is spearheading the review from their offices in the Empire State Building.
Investors holding common stock in BioLife Solutions, traded as NASDAQ: BLFS, are encouraged to review the transaction details. The firm is currently offering free consultations to shareholders seeking to understand their legal position regarding the merger. Those interested in the inquiry can reach the firm at (212) 971-1341 or via email to assess whether the proposed compensation reflects the company’s true market value.
Comments (0)
No comments yet. Be the first!